Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 1, 2008Archives of Dermatology

Safety and Efficacy of ABT-874, a Fully Human Interleukin 12/23 Monoclonal Antibody, in the Treatment of Moderate to Severe Chronic Plaque Psoriasis

View Full Paper
Ask AI
Bookmark
Share

Authors

AKAlexa B. KimballBeth Israel Deaconess Medical Center

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Alexa B. Kimball (2008) studied this question.

synapsesocial.com/papers/6a7bf99e351d91d38cc6429chttps://doi.org/10.1001/archdermatol.2007.63
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1In Vitro and In Situ Expression of IL-23 by Keratinocytes in Healthy Skin and Psoriasis Lesions: Enhanced Expression in Psoriatic Skin2006 · 454 citations
  2. 2A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis2007 · 809 citations
  3. 3An International, Randomized, Double-blind, Placebo-Controlled Phase 3 Trial of Intramuscular Alefacept in Patients With Chronic Plaque Psoriasis2003 · 372 citations
  4. 4The effect of severe psoriasis on the quality of life of 369 patients2006 · 560 citations